CJC-1295 for Sale — Buyer Guide 2026
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog available in two forms — with DAC (Drug Affinity Complex) and without DAC (MOD GRF 1-29). Before purchasing from research vendors, verify batch-linked COAs confirming ≥98% purity via HPLC, clear distinction between DAC and no-DAC variants, research-use-only labeling, and transparent third-party testing.
Midwest Peptide
10% off with code SQUARETABLE10 · 30-day cookie · 10% recurring commission
What CJC-1295 Is
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone modified for extended half-life. Two variants exist: CJC-1295 with DAC (drug affinity complex), which binds to albumin for prolonged release with a half-life of 6-8 days, and CJC-1295 without DAC (also called MOD GRF 1-29), which has a shorter half-life more closely resembling endogenous GHRH pulsatility. Neither variant has FDA approval for any indication. In the research market, both forms are widely available — making variant identification a critical buyer consideration.5 Checks Before Buying
- Correct variant identification: Ensure the vendor clearly labels whether the product is CJC-1295 with DAC or without DAC (MOD GRF 1-29). These are pharmacologically different compounds with different half-lives and research profiles.
- Batch-linked third-party COA: Independent laboratory testing with HPLC chromatograms and a batch number matching the product listing. Vendors who cannot provide this should be excluded.
- Purity ≥98% confirmed analytically: Look for visible HPLC chromatograms or mass-spectrometry data. A claimed percentage without supporting analytical data is not meaningful evidence.
- Research-use-only positioning: Legitimate vendors do not offer dosing guidance, injection protocols, or health-outcome language. Vendors crossing into human-use framing are outside research-chemical norms.
- Documentation currency: COAs and lab reports should be current — ideally within 6-12 months for active inventory.
Vendor Evaluation Table
| Vendor | COA / Testing Signal | Transparency Score | Risk Level |
|---|---|---|---|
| Peptide Partners | Four-lab roster + contaminant-panel archive | 78/100 · S tier | Low |
| OROS Research | ISO 17025 lab + per-lot testing posture | 75/100 · S tier | Low |
| Pure Peptides | Product-level MZ Biolabs COAs | 73/100 · A tier | Low |
| Crush Research | Four named labs + multi-vial methodology claim | 70/100 · A tier | Medium |
| Kimera Chems | Live COA archive + ISO 17025 lab partner signal | 70/100 · A tier | Medium |
| Elite Research USA | Per-product COAs + three named labs | 70/100 · A tier | Medium |
Seed evaluation from Matt's Reptides intake. Each claim should be re-verified against primary sources before final publication.
Red Flags That Mean Walk Away
Avoid any CJC-1295 vendor that: conflates DAC and no-DAC variants without distinction, provides injection or reconstitution instructions, makes growth-hormone-boosting health claims, sells through peer marketplaces, cannot produce a batch-linked COA, or prices significantly below the peer average. CJC-1295's popularity for research purposes makes it a common counterfeit target — variant confusion may indicate poor vendor quality control.Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC contains a drug affinity complex that binds to albumin in circulation, extending the half-life dramatically (6-8 days vs. ~30 minutes for the unmodified form). CJC-1295 without DAC (also called MOD GRF 1-29) has a shorter half-life and more closely mimics the natural pulsatile release of endogenous GHRH. They are different compounds for research purposes and should not be treated as interchangeable.
Is CJC-1295 the same as GHRP-6 or ipamorelin?
No. CJC-1295 is a GHRH analog that acts on the pituitary's GHRH receptors. GHRP-6 and ipamorelin are growth hormone-releasing peptides (GHRPs) that act on ghrelin receptors. They stimulate GH release through different mechanisms and are studied for different research applications.
How do I verify a CJC-1295 COA?
A legitimate COA should come from an ISO-accredited independent laboratory, include the batch number matching the product, show HPLC chromatograms or MS data, and be dated. You should independently verify the laboratory exists and the report is accessible without a login requirement.
Has CJC-1295 been FDA-approved?
No. CJC-1295 has not received FDA approval as a pharmaceutical product for any indication. It is sold in the research market as a chemical for laboratory study only. Products are not equivalent to any FDA-approved medication.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for CJC-1295 for Sale — Buyer Guide 2026
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For cjc 1295 for sale, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →